These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 2876099)
41. Evolution of the Dmt-Tic pharmacophore: N-terminal methylated derivatives with extraordinary delta opioid antagonist activity. Salvadori S; Balboni G; Guerrini R; Tomatis R; Bianchi C; Bryant SD; Cooper PS; Lazarus LH J Med Chem; 1997 Sep; 40(19):3100-8. PubMed ID: 9301674 [TBL] [Abstract][Full Text] [Related]
42. Opioid agonist and antagonist bivalent ligands. The relationship between spacer length and selectivity at multiple opioid receptors. Portoghese PS; Larson DL; Sayre LM; Yim CB; Ronsisvalle G; Tam SW; Takemori AE J Med Chem; 1986 Oct; 29(10):1855-61. PubMed ID: 3020244 [TBL] [Abstract][Full Text] [Related]
43. Probes for narcotic receptor mediated phenomena. 13. Potential irreversible narcotic antagonist-based ligands derived from 6,14-endo-ethenotetrahydronororipavine with 7-(methoxyfumaroyl)amino, (bromoacetyl)amino, or isothiocyanate electrophiles: chemistry, biochemistry, and pharmacology. Lessor RA; Bajwa BS; Rice KC; Jacobson AE; Streaty RA; Klee WA; Smith CB; Aceto MD; May EL; Harris LS J Med Chem; 1986 Nov; 29(11):2136-41. PubMed ID: 3023609 [TBL] [Abstract][Full Text] [Related]
44. Design and synthesis of somatostatin analogues with topographical properties that lead to highly potent and specific mu opioid receptor antagonists with greatly reduced binding at somatostatin receptors. Kazmierski W; Wire WS; Lui GK; Knapp RJ; Shook JE; Burks TF; Yamamura HI; Hruby VJ J Med Chem; 1988 Nov; 31(11):2170-7. PubMed ID: 2903246 [TBL] [Abstract][Full Text] [Related]
45. 125I-DPDYN, monoiodo [D-Pro10]- dynorphin (1-11), is an effective and useful tool for the study of kappa opioid receptors. Gairin JE; Jomary C; Cros J; Meunier JC NIDA Res Monogr; 1986; 75():232-5. PubMed ID: 2893266 [TBL] [Abstract][Full Text] [Related]
46. The choice of opioid receptor subtype in isolated preparations by dynorphins. Oka T; Aoki K; Kajiwara M Life Sci; 1983; 33 Suppl 1():311-4. PubMed ID: 6141492 [TBL] [Abstract][Full Text] [Related]
47. ORL1 and opioid receptor preferences of nociceptin and dynorphin A analogues with Dmp substituted for N-terminal aromatic residues. Sasaki Y; Kawano S; Kohara H; Watanabe H; Ambo A Bioorg Med Chem; 2006 Apr; 14(7):2433-7. PubMed ID: 16321540 [TBL] [Abstract][Full Text] [Related]
48. Use of the mouse vas deferens to determine mu, delta, and kappa receptor affinities of opioid antagonists. Cohen ML; Mendelsohn LG; Mitch CH; Zimmerman DM Receptor; 1994; 4(1):43-53. PubMed ID: 8038706 [TBL] [Abstract][Full Text] [Related]
49. Effects of the substitution of Phe4 in the opioid peptide [D-Ala8]dynorphin A-(1-11)NH2. Vig BS; Zheng MQ; Murray TF; Aldrich JV J Med Chem; 2003 Sep; 46(19):4002-8. PubMed ID: 12954053 [TBL] [Abstract][Full Text] [Related]
50. Development of highly potent and selective dynorphin A analogues as new medicines. Lung FD; Chen CH; Liu JH J Pept Res; 2005 Nov; 66(5):263-76. PubMed ID: 16218994 [TBL] [Abstract][Full Text] [Related]
51. Irreversible blockade of the kappa-receptor by a newly synthesized dynorphin derivative containing a 3-nitro-2-pyridinesulfenyl group. Koike K; Takayanagi I; Hirakura Y; Matsueda R Arch Int Pharmacodyn Ther; 1991; 313():33-46. PubMed ID: 1687773 [TBL] [Abstract][Full Text] [Related]
52. Selectivities of opioid peptide analogues as agonists and antagonists at the delta-receptor. Corbett AD; Gillan MG; Kosterlitz HW; McKnight AT; Paterson SJ; Robson LE Br J Pharmacol; 1984 Sep; 83(1):271-9. PubMed ID: 6091824 [TBL] [Abstract][Full Text] [Related]
53. Design of potent dynorphin A-(1-9) analogues devoid of supraspinal motor effects in mice. Le HT; Michelot R; Dumont M; Shukla VK; Mayer M; Nguyen KP; Ruan H; Lemaire S Can J Physiol Pharmacol; 1997 Jan; 75(1):9-14. PubMed ID: 9101059 [TBL] [Abstract][Full Text] [Related]
55. Opioid activity of dermenkephalin analogues in the guinea-pig myenteric plexus and the hamster vas deferens. Sagan S; Corbett AD; Amiche M; Delfour A; Nicolas P; Kosterlitz HW Br J Pharmacol; 1991 Oct; 104(2):428-32. PubMed ID: 1665735 [TBL] [Abstract][Full Text] [Related]
56. Delta opioidmimetic antagonists: prototypes for designing a new generation of ultraselective opioid peptides. Salvadori S; Attila M; Balboni G; Bianchi C; Bryant SD; Crescenzi O; Guerrini R; Picone D; Tancredi T; Temussi PA Mol Med; 1995 Sep; 1(6):678-89. PubMed ID: 8529134 [TBL] [Abstract][Full Text] [Related]
57. Selective inactivation of opioid receptors in rat hippocampus demonstrates that dynorphin-A and -B may act on mu-receptors in the CA1 region. Chavkin C; Henriksen SJ; Siggins GR; Bloom FE Brain Res; 1985 Apr; 331(2):366-70. PubMed ID: 2859095 [TBL] [Abstract][Full Text] [Related]
58. Synthesis and opioid activities of [D-Leu-8]Dynorphin(1-8) analogs containing a reduced peptide bond, psi(CH2-NH). Ambo A; Adachi T; Sasaki Y Chem Pharm Bull (Tokyo); 1995 Sep; 43(9):1547-50. PubMed ID: 7586080 [TBL] [Abstract][Full Text] [Related]
59. Synthesis and biological evaluation of 14-alkoxymorphinans. 2. (-)-N-(cyclopropylmethyl)-4,14-dimethoxymorphinan-6-one, a selective mu opioid receptor antagonist. Schmidhammer H; Burkard WP; Eggstein-Aeppli L; Smith CF J Med Chem; 1989 Feb; 32(2):418-21. PubMed ID: 2536439 [TBL] [Abstract][Full Text] [Related]